Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M22-056 Atogepant for Prevention of Episodic Migraine in Japanese Adults
jRCT2031230217Phase 3Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of atogepant in episodic migraine (4 arms), sponsored by AbbVie Inc. Primary endpoint: Change From Baseline in Mean Monthly Migraine Days. Started Jul 2023; status: active, not recruiting.
02
Drugs
atogepant
03
Conditions
episodic migraine
Beyond the preview
Go deeper on jRCT2031230217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230217.